Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + S-1 vs Nab-paclitaxel + Gemcitabine in Advanced Pancreatic Cancer
NCT03636308Phase 2Unknown
- Sponsor
- Peking University
- Start
- Jul 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur + gimeracil + oteracil in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Peking University. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
tegafur + gimeracil + oteracil
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03636308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03636308.